Drug-Eluting Stent Benefits Do Not Outweigh Price Tag – Lancet Study
This article was originally published in The Gray Sheet
Drug-eluting stent use could be restricted to certain high-risk patient subgroups until the price of the stents is reduced, according to a cost-effectiveness study presented Sept. 6 at the European Society of Cardiology meeting in Stockholm
You may also be interested in...
Johnson & Johnson is emphasizing Cypher's low thrombosis rates after the sirolimus-eluting stent failed to show clinical superiority over Boston Scientific's Taxus
The additional costs associated with implanting Johnson & Johnson/Cordis' Cypher sirolimus-eluting stent instead of a bare metal stent are almost entirely recouped within the first year post-implant, according to a cost-effectiveness analysis of the SIRIUS trial
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.